This year we happily celebrate and share the amazing news that the FDA has approved 2 new CRISPR GENE-EDITING therapies for SCD, oKering new hope for this long-overlooked genetic illness, that causes excruciating pain and suKering, and cuts decades oK people’s lives. A new light at the end of the tunnel!!!
According to Sickle Cell Disease Association of America, SCDAA
“On Dec. 8, 2023, the Food and Drug Administration (FDA) approved two cell-based gene therapies for sickle cell disease (SCD), Casgevy from CRISPR/Vertex and Lyfgenia from bluebird bio. These are the first treatments of their kind available to individuals with SCD in the United States. SCDAA welcomes the approval of these potentially curative therapies which mark major advances in the treatment of sickle cell disease; however, there are valid concerns about accessibility and the potential for adverse effects.”